WGS (GeneDx Holdings) Debt-to-Asset : 0.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
65 GF Score
Price $90.32
GF Value $73.77
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GeneDx Holdings Debt-to-Asset?

GeneDx Holdings WGS +3.30% 65 Debt-to-Asset is 0.35 as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GeneDx Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $5.7 Mil. GeneDx Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $161.7 Mil. GeneDx Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $481.5 Mil. GeneDx Holdings's debt to asset for the quarter that ended in Jun. 2026 was 0.35.

GeneDx Holdings  (NAS:WGS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

GeneDx Holdings Debt-to-Asset Related Terms

GeneDx Holdings Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for GeneDx Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneDx Holdings Debt-to-Asset Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.02 0.16 0.29 0.28 0.22

GeneDx Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.23 0.22 0.33 0.35

WGS vs NEO, CDNA, PSNL: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, GeneDx Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneDx Holdings Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Debt-to-Asset falls into.


WGS
65GF Score
GeneDx Holdings Corp WGS
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneDx Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

GeneDx Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(8.946 + 104.222) / 523.71
=0.22

GeneDx Holdings's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.709 + 161.693) / 481.486
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.35 mean?
GeneDx Holdings (WGS) has a Debt-to-Asset of 0.35 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on GeneDx Holdings and its competitors.
Is GeneDx Holdings' Debt-to-Asset too high?
GeneDx Holdings' current Debt-to-Asset is 0.35. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Debt-to-Asset compare to NEO and CDNA?
GeneDx Holdings' Debt-to-Asset of 0.35 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on GeneDx Holdings and its competitors. GeneDx Holdings's current Debt-to-Asset is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Debt-to-Asset is 0.35. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Debt-to-Asset is 0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Debt-to-Asset: 0.35
  • GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score

Get the complete analysis for WGS

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.32
Price
$73.77
GF Value